-
Who we are
Who we are
Novavax is a global biotechnology company with a proven vaccine technology. We are focused on developing our R&D assets and establishing partnerships to leverage the value of our technology to help protect health.
Discover our scienceLearn about our validated protein-based nanoparticle and Matrix-M™ adjuvant technology.
-
What we do
What we do
Novavax is focused on using our proven vaccine technology to help protect health through the development of our R&D assets and establishing partnerships
Latest UpdatesStay current with Novavax news as we make progress in discovering and developing innovative vaccines to help protect against serious infectious diseases.
-
Blog
Blog
Novavax is committed to accelerating the development of new and promising vaccines and sharing information based on years of study and experience.
Our Partners
We seek and encourage meaningful partnerships and collaborations with leading pharmaceutical and biopharmaceutical organizations, research institutions, government agencies and foundations to further the impact of our proven technology. Some of our partnerships include:
Novavax and Sanofi have a co-exclusive licensing agreement which includes:
- Co-commercialization of Novavax’s COVID-19 Vaccine
- A sole license to develop and commercialize combination products containing Novavax’s COVID-19 vaccine and Sanofi’s seasonal influenza vaccines
- A non-exclusive license to develop and commercialize combination products containing Novavax’s COVID-19 vaccine and one or more non-influenza vaccines
- A non-exclusive license to develop and commercialize other vaccine products that include Novavax’s Matrix-M™ adjuvant
Novavax and Takeda partner on Novavax’s COVID-19 vaccine. The agreement includes an exclusive license to develop, manufacture and commercialize Novavax’s COVID-19 Vaccine in Japan.
Novavax and Serum Institute of India (SII) partner on Novavax’s COVID-19 vaccine and SII and Oxford University’s R21 Malaria program. SII has an exclusive license to market Novavax’s COVID-19 vaccine in India. Novavax provides Matrix-M™ for SII’s commercialization of its R21 malaria vaccine.
SK bioscience has an exclusive license to supply and commercialize Novavax’s COVID-19 vaccine in Korea and a non-exclusive license in Thailand and Vietnam.
Novavax is on a mission to help protect the health of people everywhere and follow the highest standards of corporate governance. Learn more about our Environmental, Social and Governance (ESG) initiatives.
As part of our Advocacy initiative, Novavax is proactively partnering with organizations with the goal of ensuring that all communities have equal access to vaccines, resources and education.